LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

ABT

134.76

+1.17%↑

Search

Novo Nordisk A-S

Slēgts

SektorsVeselības aprūpe

64.34 -2.56

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

63.15

Max

66.07

Galvenie mērījumi

By Trading Economics

Ienākumi

804M

29B

Pārdošana

-7.6B

78B

P/E

Sektora vidējais

19.19

56.602

EPS

6.53

Dividenžu ienesīgums

2.39

Peļņas marža

37.182

Darbinieki

76,302

EBITDA

5.9B

46B

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+39.24% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

2.39%

2.45%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

29B

295B

Iepriekšējā atvēršanas cena

66.9

Iepriekšējā slēgšanas cena

64.34

Ziņu noskaņojums

By Acuity

31%

69%

88 / 382 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Novo Nordisk A-S Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. maijs 09:36 UTC

Galvenie tirgus virzītāji

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

2025. g. 7. maijs 11:29 UTC

Top Ziņas
Peļņas
Galvenie tirgus virzītāji

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs -- 2nd Update

2025. g. 7. maijs 07:05 UTC

Peļņas

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales -- Update

2025. g. 7. maijs 06:19 UTC

Peļņas

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales

2025. g. 12. maijs 22:14 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

2025. g. 12. maijs 18:45 UTC

Top Ziņas

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

2025. g. 12. maijs 12:07 UTC

Tirgus saruna

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

2025. g. 12. maijs 07:20 UTC

Tirgus saruna

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

2025. g. 7. maijs 15:13 UTC

Peļņas

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Arista, Sarepta, Charles River, and More -- Barrons.com

2025. g. 7. maijs 13:56 UTC

Peļņas

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

2025. g. 7. maijs 13:45 UTC

Peļņas

These Stocks Are Moving the Most Today: Super Micro, AMD, Marvell, Disney, Uber, Nordisk, Sarepta, EA, Upstart, and More -- Barrons.com

2025. g. 7. maijs 11:25 UTC

Peļņas

These Stocks Are Moving the Most Today: Super Micro, AMD, Disney, Uber, Novo Nordisk, Sarepta, EA, Tesla, and More -- Barrons.com

2025. g. 7. maijs 11:18 UTC

Peļņas

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

2025. g. 7. maijs 09:55 UTC

Peļņas

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Disney, and More -- Barrons.com

2025. g. 7. maijs 09:36 UTC

Peļņas

These Stocks Are Moving the Most Today: Super Micro, AMD, Novo Nordisk, Sarepta, EA, Rivian, Tesla, and More -- Barrons.com

2025. g. 7. maijs 09:04 UTC

Peļņas
Karstas akcijas

Stocks to Watch Wednesday: Disney, Uber, Super Micro -- WSJ

2025. g. 7. maijs 08:10 UTC

Tirgus saruna

Novo Nordisk Cuts Guidance Slightly More Than Expected -- Market Talk

2025. g. 7. maijs 08:08 UTC

Tirgus saruna

Novo Nordisk's Downgraded Guidance Assumes Large Wegovy Uplift in 2H -- Market Talk

2025. g. 7. maijs 07:11 UTC

Tirgus saruna
Peļņas

Novo Nordisk Shares Seen Under Pressure After Downgrade -- Market Talk

2025. g. 7. maijs 05:39 UTC

Peļņas

Novo Nordisk: Sales Outlook Assumes Reduction in Patients on Compounded GLP-1 Treatments During 2H25

2025. g. 7. maijs 05:38 UTC

Peļņas

Novo Nordisk 1Q Wegovy Drug Sales Rose 83% To DKK17.36B, Consensus Saw DKK18.5B

2025. g. 7. maijs 05:37 UTC

Peļņas

Novo Nordisk 1Q Ozempic Drug Sales Rose 15% To DKK32.72B, Consensus Saw DKK32.01B

2025. g. 7. maijs 05:36 UTC

Peļņas

Novo Nordisk 1Q Gross Margin 83.5% Vs 84.8%

2025. g. 7. maijs 05:35 UTC

Peļņas

Novo Nordisk: Focused on Preventing Unlawful Compounding and Further Expanding Access in US

2025. g. 7. maijs 05:34 UTC

Peļņas

Novo Nordisk: US Sales of Branded GLP-1 Treatments Impacted By Compounded Versions

2025. g. 7. maijs 05:34 UTC

Peļņas

Novo Nordisk: Sales Outlook Reflects Lower-Than-Planned Penetration of Branded GLP-1 Treatments in US

2025. g. 7. maijs 05:33 UTC

Peļņas

Novo Nordisk: Had Seen 2025 Op Profit Growth of 19%-27% in Constant Currency

2025. g. 7. maijs 05:33 UTC

Peļņas

Novo Nordisk: Had Seen 2025 Sales Growth of 16%-24% in Constant Currency

2025. g. 7. maijs 05:33 UTC

Peļņas

Novo Nordisk Now Sees 2025 Op Profit Growth of 16%-24% in Constant Currency

2025. g. 7. maijs 05:32 UTC

Peļņas

Novo Nordisk Now Sees 2025 Sales Growth of 13%-21% in Constant Currency

Salīdzinājums

Cenas izmaiņa

Novo Nordisk A-S Prognoze

Cenas mērķis

By TipRanks

39.24% augšup

Prognoze 12 mēnešiem

Vidējais 92.11 USD  39.24%

Augstākais 136.647 USD

Zemākais 61 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Novo Nordisk A-S — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

9 ratings

3

Pirkt

5

Turēt

1

Pārdot

Tehniskais rādītājs

By Trading Central

62.63 / 69.23Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

88 / 382 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.